Patrick Smith Sells 10,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock

July 1, 2026 by InsiderTrades.com

Key Points

Axon CEO Patrick Smith sold 10,000 shares on June 29 at an average price of $500, for total proceeds of $5 million. The sale was disclosed in an SEC filing and was made under a pre-arranged Rule 10b5-1 plan.
Axon shares were rising sharply, opening at $560.61 and trading up 9.8% on Wednesday. The company’s market value was about $45.19 billion, and the stock has traded between $339.01 and $885.91 over the past 52 weeks.
Recent fundamentals and analyst sentiment remain supportive, with Axon reporting quarterly revenue of $807.35 million, up 33.7% year over year, and earnings slightly above expectations. Analysts are broadly positive, with a consensus rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CEO Patrick Smith sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $500.00, for a total transaction of $5,000,000.00. Following the completion of the transaction, the chief executive officer owned 3,050,997 shares of the company's stock, valued at approximately $1,525,498,500. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise Trading Up 9.8%

Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name

Shares of AXON stock opened at $560.61 on Wednesday. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The firm has a market capitalization of $45.19 billion, a PE ratio of 225.14, a PEG ratio of 10.42 and a beta of 1.45. The stock has a fifty day simple moving average of $426.15 and a two-hundred day simple moving average of $481.27.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The business's quarterly revenue was up 33.7% compared to the same quarter last year. On average, analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Analyst Ratings Changes

Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar

A number of research analysts have recently weighed in on the company. Piper Sandler restated an "overweight" rating and set a $674.00 price objective on shares of Axon Enterprise in a research report on Monday, June 15th. Weiss Ratings upgraded Axon Enterprise from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, May 8th. Barclays reduced their price objective on Axon Enterprise from $682.00 to $523.00 and set an "overweight" rating on the stock in a research note on Friday, May 8th. UBS Group decreased their price objective on Axon Enterprise from $570.00 to $440.00 and set a "neutral" rating on the stock in a report on Thursday, May 7th. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $700.00 target price on shares of Axon Enterprise in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $712.75.

Read Our Latest Stock Analysis on AXON

Axon Enterprise News Roundup

Axon Surged After Earnings and Is Still Down Over 50% From Highs

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: News that President Trump bought Axon shares and that ICE later sought a large Taser contract has fueled speculation about future government demand for Axon’s products. Trump bought as much as $5 million in Axon stock before ICE sought $220 million Taser deal
Positive Sentiment: Axon’s recent operating momentum is also supporting the stock, including first-quarter revenue growth of 34% year over year and management’s raised 2026 growth outlook. Axon Enterprise jumps as investors react to disclosure-linked contract narrative and strong operating momentum
Neutral Sentiment: Analysts remain generally constructive, with Northland Securities reiterating a buy rating and several recent price targets clustering well above prior trading levels. Northland Securities Reaffirms Their Buy Rating on Axon Enterprise (AXON)
Neutral Sentiment: One headline also noted ongoing debate about valuation and whether the stock’s recent rebound is being driven more by momentum and political headlines than fundamentals. Axon Enterprise (AXON) Stock After Recent Volatility Is The Current Price Justified
Negative Sentiment: The Trump-Axon-ICE connection has also raised ethics and conflict-of-interest questions, which could create political and reputational risk around government contracting. Axon Enterprise (AXON) Stock Drew Ethics Questions After Trump Bought $5 Million In Shares
Negative Sentiment: Insider selling remains a headwind for sentiment, with the CEO recently selling shares under a pre-arranged trading plan and no insider purchases reported in the last six months. Axon Enterprise Stock Performance

Institutional Trading of Axon Enterprise

Several hedge funds have recently made changes to their positions in AXON. Evergreen Capital Management LLC grew its position in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after acquiring an additional 15 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Axon Enterprise by 0.5% during the third quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company's stock worth $2,848,000 after acquiring an additional 19 shares during the last quarter. CWA Asset Management Group LLC raised its position in Axon Enterprise by 5.2% during the fourth quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company's stock valued at $220,000 after purchasing an additional 19 shares during the period. Synergy Financial Group LTD raised its position in Axon Enterprise by 1.4% during the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company's stock valued at $996,000 after purchasing an additional 19 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company's stock valued at $1,350,000 after purchasing an additional 19 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.